A three-dimensional quantitative structure-activity relationship study of heparin-binding epidermal growth factor shedding inhibitors using comparative molecular field analysis

Roberta Bursi, Masaaki Sawa, Yasuyuki Hiramatsu, Hirosato Kondo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Despite the lack of structural information on the heparin-binding (HB) epidermal growth factor (EGF) shedding putative target enzyme, the design of potent HB-EGF shedding inhibitors has been attempted by means of comparative molecular field analysis (CoMFA), a well-established 3D-QSAR technique. Two different binding modes, obtained by docking a flexible representative into the MMP-3 and TACE target enzymes, were considered as alignment rules for an in-house data set of 50 HB-EGF shedding inhibitors. CoMFA models were derived with the standard steric, electrostatic, and Bohacek and McMartin's H-bond molecular fields. These fields were used individually or in combination. For both alignments, the H-bond field alone yielded the best statistical models. From the analysis of the CoMFA contours, ideas for testing the size of the S1′ pocket and suggestions for the design of new inhibitors came forward, resulting in the synthesis and testing of four new inhibitors. Three of four compounds turned out to possess from good (IC50= 0.56 and 0.60 μM) to excellent (IC50 = 0.13 μM) inhibitory activity. The hypothesis that, upon binding, the S1′ pocket in the vicinity of the R1 benzene ring must be narrow in size was confirmed by the weak activity (IC50 = 1.1 μM) of the fourth compound. The experimental profile of these new inhibitors does suggest the MMP-3 alignment as the most plausible one for HB-EGF shedding inhibitors.

Original languageEnglish
Pages (from-to)781-788
Number of pages8
JournalJournal of Medicinal Chemistry
Volume45
Issue number4
DOIs
Publication statusPublished - Feb 14 2002
Externally publishedYes

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this